NeXT Personal™ The Next Generation in Molecular Residual Disease Testing and Variant Monitoring for Solid Tumors Delivering Industry-Leading Sensitivity to Detect Residual Disease and Recurrence at the Earliest Timepoints NeXT Personal, an advanced, personalized, and tumor-informed liquid biopsy assay, is designed to detect molecular residual disease (MRD) and cancer recurrence at [...]
Pharma Research Solutions Comprehensive genomics for drug discovery and preclinical development Genomic Insights for Optimizing Drug DevelopmentWith our Pharma Research Services portfolio of broad-content next-generation sequencing (NGS) assays and analytics, we can comprehensively address the needs of biopharmaceutical companies who wish to integrate high quality and high-accuracy genomic and/or transcriptomic [...]
Biomarker Discovery Solutions for Lymphoma and Multiple Myeloma Comprehensive Characterization of Genetic Events With Combinatorial DNA and RNA Profiling The ImmunoID NeXT Platform® offers customers an optimized assay by combining highly-sensitive, exome-scale DNA and RNA sequencing, along with fully integrated advanced analytics to provide a multidimensional view of the [...]
Biomarker Discovery Solutions ImmunoID NeXT™ for Tumor Immunogenomics Elucidate Tumor-Immune Interactions from a Single Sample In the immuno-oncology era, it’s becoming clear that understanding and improving response to cancer immunotherapies relies on the study of the interactions between tumor cells and immune cells in the Tumor Microenvironment (TME). Traditionally, gaining molecular [...]
Find the answers to the most complex biological questions, with augmented NGS Find the answers to the most complex biological questions, with augmented NGS Finding the answers to complex biological questions, requires a deeper understanding of cancer biology. Personalis ACE Cancer Exome and ACE Cancer Transcriptome features augmented DNA and RNA sequencing for [...]
Checkpoint inhibitors and modulators have shown great promise in the treatment of cancer, but response rates have been limited.
